Key Highlights

  • US Centers for Medicare & Amp ; Medicaid Services proposed a coverage determination for AOTI's topical oxygen therapy in diabetic foot ulcers.
  • H1 2026 Revenue rose 10% to approximately $35 million, or 18% underlying excluding the Arizona Medicaid wind-down.
  • AOTI holds an estimated 75% share of the topical oxygen therapy segment in the US.
  • Management estimates the addressable market could expand roughly 65-fold to about $26 billion if Medicare coverage is finalised.
  • The proposal now enters a 45-day comment period, with a final decision expected within about a year.

Wound-care specialist AOTI Inc says a proposed US Medicare coverage decision for its topical oxygen therapy could unlock a market 65 times larger than today's, as half-year revenue rose to roughly $35 million despite the planned exit from Arizona Medicaid.

AOTI, Inc (LSE:AOTI), the LSE-listed wound-care company behind the TWO2 topical oxygen therapy, has told investors that a proposed US Medicare coverage decision represents a potentially transformative moment for the Business . The announcement, made on 24 July 2026, was followed days later by a half-year update confirming revenue growth of 10% to approximately $35 million, even as the group unwound a troubled Arizona Medicaid contract.

Together, the disclosures give shareholders their clearest picture yet of how AOTI's core US business is performing, and how large the prize might be if regulators extend Medicare reimbursement to topical oxygen therapy for diabetic foot ulcers.

What Happened

On 24 July, AOTI announced that the Centers for Medicare & Medicaid Services (CMS) had issued a proposed Local Coverage Determination (LCD) affirming that topical oxygen therapy is "reasonable and necessary" for treating diabetic foot ulcers that have failed to heal after four weeks of optimised care. The proposal now enters a 45-day comment period, after which CMS is expected to finalise the LCD within a year.

Three days later, on 27 July, the company published a half-year trading statement covering the six months to 30 June 2026. Revenue rose 10% to approximately $35 million, up from $31.8 million in H1 2025. Stripping out the wind-down of Arizona Medicaid, underlying growth was 18%, which chief executive Dr Mike Griffiths described as "notably ahead of our previously published guidance of mid-teens for the full year."

Griffiths called the CMS proposal "undoubtedly a significant milestone." "Once the LCD is finalised, the resulting mandated Medicare coverage will be transformative for AOTI," he said.

Why It Matters

Medicare currently does not routinely reimburse topical oxygen therapy for diabetic foot ulcers, so AOTI's US revenue has been built almost entirely on the Veterans Administration and state Medicaid programmes. A finalised LCD would mandate coverage criteria and reimbursement across the roughly 69 million Americans enrolled in Medicare, a population with a 32% diabetes prevalence rate and around 13% incidence of diabetic foot ulcers, per the company's figures.

AOTI already holds an estimated 75% share of the topical oxygen therapy segment, giving it a strong starting position should coverage arrive. It frames its current addressable market, excluding Medicare, at around $400 million, against an estimated $26 billion longer-term market once Medicare is included — a roughly 65-fold expansion, though that remains a management estimate rather than a guaranteed outcome.

Latest Financial and Operational Performance

The half-year numbers show a business growing steadily but navigating structural noise. Reported H1 2026 revenue of approximately $35 million compares with $31.8 million in H1 2025, a 10% increase; underlying growth, adjusting for the phased Arizona exit, was 18%.

By channel, the Veterans Administration remained the largest contributor at approximately 57% of revenues, growing 15%. Medicaid contributed around 41%, with underlying growth of 21%, though reported Medicaid growth was just 2% once the Arizona effect was stripped out.

Cash stood at approximately $13.8 million at 30 June 2026, with net Debt of around $6.3 million, up from $5.4 million a year earlier but broadly in line with FY2025's $6.5 million. Full interim results, including profitability metrics, are due on 30 September 2026.

For context, FY2025 revenue was approximately $66.5 million, up 14% on FY2024's $58.4 million, with an adjusted EBITDA Margin around 10.8%. Arizona Medicaid receivables had swelled to $15.6 million by end-FY2025 amid persistent reimbursement disputes, prompting the board to cease treating new patients there from 1 April 2026.

Key Numbers

  • H1 2026 revenue: approximately $35 million, up 10% year-on-year (H1 2025: $31.8 million)
  • Underlying revenue growth (excluding Arizona Medicaid): 18%
  • FY2025 full-year revenue: approximately $66.5 million, up 14% (FY2024: $58.4 million)
  • Cash at 30 June 2026: approximately $13.8 million; net debt approximately $6.3 million
  • Veterans Administration: approximately 57% of H1 2026 revenue, up 15% year-on-year
  • Medicaid: approximately 41% of H1 2026 revenue, up 21% on an underlying basis
  • Current topical oxygen therapy Market Share : approximately 75%
  • Estimated current serviceable market: approximately $400 million; estimated longer-term market including Medicare: approximately $26 billion

Growth Opportunities

The proposed Medicare LCD is the standout catalyst. If finalised broadly as proposed, it would give TWO2 a route into a Medicare population many times larger than AOTI's existing VA and Medicaid base, with clinical data pointing to an 88% reduction in hospitalisations and a 71% reduction in amputations over 12 months.

Beyond Medicare, AOTI continues building out its US footprint, with commercial infrastructure now covering 26 states and reaching an estimated 86% of the population. Growth in VA penetration and Medicaid states outside Arizona gives management momentum independent of the Medicare decision, evidenced by growth running ahead of its own mid-teens guidance in the first half.

Risks Investors Should Know

The central risk is that the proposed LCD is not yet final. CMS must complete a 45-day comment period and a review process that could take up to a year, and the eventual coverage criteria, reimbursement rates or timeline could differ from what has been proposed. Nothing here guarantees the outcome investors are hoping for.

The Arizona Medicaid episode is a reminder that state-level payer relationships can sour quickly, with receivables ballooning to $15.6 million before the company exited new patient treatment there. AOTI also flagged "headwinds from the One Big Beautiful Bill Act," US legislation affecting Medicaid funding, as an ongoing pressure. Net debt has risen year-on-year, and Operating Cash Flow was negative in the prior comparable half, underlining that growth has come with continued cash consumption.

What to Watch Next

Investors should watch the outcome of the 45-day CMS comment period, progress toward a final LCD over the coming year, and the interim results due 30 September 2026, which should add profitability and cash-flow detail to the top-line figures already disclosed.

Outlook

AOTI's July announcements gave shareholders a genuine, if conditional, reason for optimism: a Medicare pathway that could reshape its addressable market, alongside revenue growth ahead of guidance even as the company works through the Arizona Medicaid unwind. The opportunity is real, but so is the uncertainty until CMS delivers a final decision.